Netherlands· NL-d2eaa766c2c0

Mavenclad 10 mg tabletten

A cladribine product containing cladribine, registered in Netherlands by Merck Europe B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC L04AA40

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about cladribineAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Cladribine is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AA40 (cladribine), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search cladribine products by name

Cladribine · ATC L04AA40

12 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cladribine costs, country by country.

Normalised to the WHO defined daily dose (0.34 mg), the median price runs from $0.048 in France to $90.83 in Switzerland — a ×1908 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Cladribine · price per daily dose (0.34 mg)

USD · FX 28 Sept 2026

CH Switzerland$90.83
FR France$0.048

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: CLADRIBINE
Manufacturer: Merck Europe B.V.
Country: Netherlands (NL)
ATC code: L04AA40
ATC class: Cladribine
Defined daily dose: 0.34 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/17/1212

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

409 interactions on record for cladribine.

Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check cladribine against other medicines How interaction checks work

Cladribine · interactions on record

409 records

326 severe
79 moderate
4 info

Most severe, free to view

PrednisoloneA07EA01severe
HydrocortisoneA07EA02severe
PrednisoneA07EA03severe
BetamethasoneA07EA04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cladribine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cladribine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

Austria · Leuject
Belgium · Leustatin
Bulgaria · Леуджект
Czechia · Leuject
Germany · Leustatin
Spain · Leustatin
Finland · Leuject
France · Leustatine
United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
Greece · Leustatin
Croatia · Leuject
Hungary · Leuject
Iceland · Mavenclad
Italy · Leustatin
Liechtenstein · Mavenclad
Luxembourg · Leustatin
Norway · Leuject, Mavenclad
Poland · Biodribin, Leuject
Portugal · Cladribina Generis, Leustatin
Romania · Leuject
Sweden · Leuject
Slovenia · Leuject

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/643d196a-1d43-4518-8b39-f3a3c0a289b7
GET /v1/drugs/643d196a-1d43-4518-8b39-f3a3c0a289b7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Cladribine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp119639",
  "excipients": [
    "HYDROXYPROPYLBETADEX",
    "MAGNESIUMSTEARAAT (E 470b)",
    "SORBITOL (E 420)"
  ],
  "substances": [
    "CLADRIBINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/08/22",
  "procedure_number": "EMEA/H/C/004230",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1212",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about cladribine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console